Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376637 | 0.84 | CHRM3 (0.49) | L3MBTL1HRH3ALDH1A1CHRM3ABCG2 | |
| SCHEMBL13929716 | 0.84 | CHRNB2 (0.48) | HRH3CHRM3KMT2A | |
| SCHEMBL8525958 | 0.81 | KMT2A (0.40) | L3MBTL1HRH3ALDH1A1KMT2AKDM4E | |
| SCHEMBL14376121 | 0.81 | CHRM3 (0.46) | L3MBTL1ALDH1A1CHRM3ABCG2HTT | |
| SCHEMBL14376698 | 0.80 | CHRM3 (0.48) | L3MBTL1ALDH1A1CHRM3ABCG2TSHR | |
| SCHEMBL14350144 | 0.80 | KMT2A (0.40) | L3MBTL1HRH3ALDH1A1KMT2ATSHR | |
| SCHEMBL12464692 | 0.79 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1CHRM3KMT2AABCG2 | |
| SCHEMBL14376725 | 0.79 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1CHRM3KMT2AABCG2 | |
| SCHEMBL13407275 | 0.79 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1CHRM3KMT2AABCG2 | |
| SCHEMBL14376852 | 0.78 | CHRM3 (0.49) | L3MBTL1ALDH1A1CHRM3KMT2AABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | L3MBTL1 3498/4885HRH3 72/4885ALDH1A1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.